Skip to main content
Home
Home

  • People
  • Events
    AIHC New
    Science and Technology Policy
    Tue, Sep. 15 - Thu, Sep. 17, 2026 | 8 am - 6 pm
    AI in Health Conference See Details
    SynBio-Crop
    Science and Technology Policy
    Fri, Sep. 18, 2026 | 9 am - 5 pm
    Synthetic Biology at the Intersection of Science, Ethics, and Policy See Details
    Ellen Ochoa Image
    Science and Technology Policy
    Mon, Nov. 02, 2026 | 5:30 pm - 7:30 pm
    Joni Sue Lane Lecture Series — Exploring Space: A Conversation With Astronaut Ellen Ochoa See Details
  • Podcasts
  • Research Programs
  • Research & Commentary
  • Press
  • Support
  • About
  • Newsletter
  • Search
  • Research
  • Twitter
  • Facebook
  • instagram
  • Linkedin
  • Youtube
  • Newsletter
  • Economics & Finance
  • Energy
  • Foreign Policy
  • Domestic Policy
  • Health & Science
  • All Publications
Center for Health Policy | Journal

Unproven Stem Cell-Based Interventions: Addressing Patients’ Unmet Needs or Causing Patient Harms?

January 2, 2023 | Kirstin R.W. Matthews
Blue stem cell under microscope

Table of Contents

Author(s)

Kirstin Matthews headshot

Kirstin R.W. Matthews

Fellow in Science and Technology Policy
Read More

Share this Publication

  • Facebook
  • Twitter
  • Email
  • Linkedin
  • Print This Publication
  • Cite This Publication

    K.R.W Matthews, "Unproven Stem Cell-Based Interventions: Addressing Patients’ Unmet Needs or Causing Patient Harms?" (Houston: Rice University’s Baker Institute for Public Policy, January 2, 2023), https://doi.org/10.1007/978-3-031-12692-5_6.

    Copy Citation

Abstract

Scholars began reporting about this marketplace in the mid-2000s; however, there is no sign of it dissipating despite efforts from regulators and scientific societies. While there have been periodic and repeated calls for a global approach to combat the unproven stem cell intervention (SCI) market, little action has been taken.

In this chapter, I will define unproven SCI, describe the marketplace, and discuss the risks to patients, clinical research, and regulatory authorities as well as the discontent between patients and regulators regarding what is safe to use in the clinic. I will also review current regulatory efforts to curb the market’s growth. Finally, I will argue for a series of strategies will be presented that can better inform patients and harmonize regulatory efforts between countries.

Access the full chapter in Medical Research Ethics: Challenges in the 21st Century.

https://doi.org/10.1007/978-3-031-12692-5_6
  • Print This Publication
  • Share
    • Facebook
    • Twitter
    • Email
    • Linkedin

Related Research

Flooded cars on the street of the city.
Center for Health Policy | Podcast

What FEMA’s New Flood Maps Mean for Houston Schools

Read More
CBD Hemp Infused Gummy Slices
Center for Health Policy | Podcast

How Texas Hemp Regulations Affect Youth Safety

Read More
Yellow ambulance on a dirt road: medical transport in rural area
Center for Health Policy | Policy Brief

Health-Related Social Needs as a Rural Health Transformation Strategy

Read More
  • Contact Us
  • Donate Now
  • Press
  • Membership
  • Careers
  • Student Opportunities
  • About the Institute
  • Rice.edu

6100 Main Street
Baker Hall MS-40, Suite 120
Houston, TX 77005

Email: [email protected]
Phone: 713-348-4683
Fax: 713-348-5993

  • Twitter
  • Facebook
  • instagram
  • Linkedin
  • Youtube
  • Newsletter
  • © Rice University's Baker Institute for Public Policy
  • Web Accessibility
  • Privacy Policy